Phase II Study of Lutetium-177-Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer

177Lu-labeled PSMA targeting therapeutic with optimized linker for treatment of disseminated prostate cancer; evaluation of biodistribution and dosimetry

Abouzayed, Ayman
Seitova, Kamila
Lundmark, Fanny
Bodenko, Vitalina
Oroujeni, Maryam
Tolmachev, Vladimir
Rosenström, Ulrika
Orlova, Anna

January 2023

<bold>Introduction:</bold> Prostate specific membrane antigen (PSMA), highly expressed i...

Antibodies targeting Prostate-Specific Membrane Antigen positive prostate cancer: from diagnostic imaging to theranostics

Roumeguere T.
Aoun F.
Albisinni S.
Mjaess G.

January 2021

Purpose of review Targeting Prostate-Specific Membrane Antigen (PSMA) has paved the way for personal...

Projections for 90Y Radioimmunotherapy

In-j Lesion Detectability
Neeta P
Joseph A. O’donoghue
Michael J. Morris
Eze A. Wills
Lawrence H. Schwartz
Mithat Gonen
Howard I. Scher
Steven M. Larson
Chaitanya R. Divgi

December 2014

J591, a monoclonal antibody that targets the external domain of the prostate-specific membrane antig...

Phase II Study of Lutetium-177-Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer

Tagawa, Scott T.
Milowsky, Matthew I.
Morris, Michael
Vallabhajosula, Shankar
Christos, Paul
Akhtar, Naveed H.
Osborne, Joseph
Goldsmith, Stanley J.
Larson, Steve
Taskar, Neeta Pandit
Scher, Howard I.
Bander, Neil H.
Nanus, David M.

January 2013

To assess the efficacy of a single infusion of radiolabeled anti-prostate specific membrane antigen ...

Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer

Matthew I. Milowsky
David M. Nanus
Lale Kostakoglu
Shankar Vallabhajosula
Stanley J. Goldsmith
Neil H. B

January 2004

To determine the maximum-tolerated dose (MTD), toxicity, human antihuman antibody (HAHA) response, p...

Prostate-Specific Membrane Antigen-Based Therapeutics

Naveed H. Akhtar
Orrin Pail
Ankeeta Saran
Lauren Tyrell
Scott T. Tagawa

January 2012

Prostate cancer (PC) is the most common noncutaneous malignancy affecting men in the US, leading to ...

Clinical Variables Associated with PSA Response to Lutetium-177-PSMA ([177Lu]-PSMA-617) Radionuclide Treatment in Men with Metastatic Castration-Resistant Prostate Cancer

Gadot, Moran
Davidson, Tima
Aharon, Margalit
Atenafu, Eshetu G.
Malki, Avraham
Levartovsky, Meital
Saad, Akram
Domachevsky, Liran
Berger, Raanan
Leibowitz, Raya

April 2020

Lutetium-177-PSMA ([177Lu]-PSMA-617), a radiolabeled small molecule, binds with high affinity to pro...

Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.

Sartor, O
de Bono, J
Chi, KN
Fizazi, K
Herrmann, K
Rahbar, K
Tagawa, ST
Nordquist, LT
Vaishampayan, N
El-Haddad, G
Park, CH
Beer, TM
Armour, A
Pérez-Contreras, WJ
DeSilvio, M
Kpamegan, E
Gericke, G
Messmann, RA
Morris, MJ
Krause, BJ
VISION Investigators

June 2021

Background Metastatic castration-resistant prostate cancer remains fatal despite recent advances. Pr...

PSMA Theranostics: Current Status and Future Directions

Rahbar, Kambiz
Afshar Oromieh, Ali
Jadvar, Hossein
Ahmadzadehfar, Hojjat

January 2018

Prostate-specific membrane antigen (PSMA) is a promising target for imaging diagnostics and targeted...

Single-lesion Prostate-specific Membrane Antigen Protein Expression (PSMA) and Response to [177Lu]-PSMA-ligand Therapy in Patients with Castration-resistant Prostate Cancer

Judith Stangl-Kremser
Sazan Rasul
Jeffrey J. Tosoian
Simpa S. Salami
Alexander Zaslavsky
Aaron Udager
Peter Mazal
Renate Kain
Eva Comperat
Marcus Hacker
Alexander Haug
Markus Mitterhauser
Carmen Pozo-Salido
Christina Steinbach
Melanie R. Hassler
Gero Kramer
Shahrokh F. Shariat
Ganesh S. Palapattu

August 2021

Initial reports of a clinical response in patients treated with the radioligand [177Lu]-PSMA-617 for...

Real-world Outcomes and Predictive Biomarkers for 177Lutetium Prostate-specific Membrane Antigen Ligand Treatment in Metastatic Castration-resistant Prostate Cancer: A European Association of Urology Young Academic Urologists Prostate Cancer Working Group Multi-institutional Observational Study

Kafka, Mona
Horninger, Andreas
di Santo, Gianpaolo
Virgolini, Irene
Neuwirt, Hannes
Unterrainer, Lena M
Kunte, Sophie C
Deiss, Emil
Paffenholz, Pia
Heidenreich, Axel
Rasul, Sazan
Einspieler, Holger
Shariat, Shahrokh F
Rajwa, Pawel
Dozauer, Robert
Tsaur, Igor
Medlock, Ellen
Rölz, Niklas
Rausch, Steffen
la Fougère, Christian
Trautwein, Nils
Roesch, Marie C
Merseburger, Axel S
Zattoni, Fabio
Sepulcri, Matteo
Ladurner, Michael
Bektic, Jasmin
Gandaglia, Giorgio
Horninger, Wolfgang
Heidegger, Isabel

January 2023

Background: The European Association of Urology guidelines include the lutetium-177 (177Lu) PSMA-617...

USE OF 177Lu-PSMA FOR RADIONUCLIDE THERAPY IN PATIENTS WITH CASTRATE-RESISTANT PROSTATE CANCER

A. A. Medvedeva
V. I. Chernov
E. A. Usynin
R. V. Zelchan
O. D. Bragina
N. A. Lushnikova

June 2021

Purpose of the study: to present current data regarding challenges in treatment of castration-resist...

Near Complete Response to 177Lu-PSMA-DKFZ-617 Therapy in a Patient with Metastatic Castration Resistant Prostate Cancer

Madhav Prasad Yadav (4852228)
Sanjana Ballal (4852222)
Chandrasekhar Bal (4852225)

February 2018

Prostate specific membrane antigen, a type II transmembrane protein is an excellent target for th...

Preliminary experience with dosimetry, response and patient reported outcome after Lu-177-PSMA-617 therapy for metastatic castration-resistant prostate cancer

Fendler, Wolfgang P.
Reinhardt, Svenja
Ilhan, Harun
Delker, Andreas
Böning, Guido
Gildehaus, Franz J.
Stief, Christian
Bartenstein, Peter
Gratzke, Christian
Lehner, Sebastian
Rominger, Axel

January 2017

Prostate cancer can be targeted by ligands to the prostate-specific membrane antigen (PSMA). We aime...

Targeted Therapy for Metastatic Prostate Cancer with Radionuclides

Ahmadzadehfar, Hojjat

September 2016

Progression to androgen-independent status is the main cause of death in patients with metastatic pr...

177Lu-labeled PSMA targeting therapeutic with optimized linker for treatment of disseminated prostate cancer; evaluation of biodistribution and dosimetry

Abouzayed, Ayman
Seitova, Kamila
Lundmark, Fanny
Bodenko, Vitalina
Oroujeni, Maryam
Tolmachev, Vladimir
Rosenström, Ulrika
Orlova, Anna

January 2023

<bold>Introduction:</bold> Prostate specific membrane antigen (PSMA), highly expressed i...

Antibodies targeting Prostate-Specific Membrane Antigen positive prostate cancer: from diagnostic imaging to theranostics

Roumeguere T.
Aoun F.
Albisinni S.
Mjaess G.

January 2021

Purpose of review Targeting Prostate-Specific Membrane Antigen (PSMA) has paved the way for personal...

Projections for 90Y Radioimmunotherapy

In-j Lesion Detectability
Neeta P
Joseph A. O’donoghue
Michael J. Morris
Eze A. Wills
Lawrence H. Schwartz
Mithat Gonen
Howard I. Scher
Steven M. Larson
Chaitanya R. Divgi

December 2014

J591, a monoclonal antibody that targets the external domain of the prostate-specific membrane antig...

Phase II Study of Lutetium-177-Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer

Tagawa, Scott T.
Milowsky, Matthew I.
Morris, Michael
Vallabhajosula, Shankar
Christos, Paul
Akhtar, Naveed H.
Osborne, Joseph
Goldsmith, Stanley J.
Larson, Steve
Taskar, Neeta Pandit
Scher, Howard I.
Bander, Neil H.
Nanus, David M.

January 2013

To assess the efficacy of a single infusion of radiolabeled anti-prostate specific membrane antigen ...

Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer

Matthew I. Milowsky
David M. Nanus
Lale Kostakoglu
Shankar Vallabhajosula
Stanley J. Goldsmith
Neil H. B

January 2004

To determine the maximum-tolerated dose (MTD), toxicity, human antihuman antibody (HAHA) response, p...

Prostate-Specific Membrane Antigen-Based Therapeutics

Naveed H. Akhtar
Orrin Pail
Ankeeta Saran
Lauren Tyrell
Scott T. Tagawa

January 2012

Prostate cancer (PC) is the most common noncutaneous malignancy affecting men in the US, leading to ...

Clinical Variables Associated with PSA Response to Lutetium-177-PSMA ([177Lu]-PSMA-617) Radionuclide Treatment in Men with Metastatic Castration-Resistant Prostate Cancer

Gadot, Moran
Davidson, Tima
Aharon, Margalit
Atenafu, Eshetu G.
Malki, Avraham
Levartovsky, Meital
Saad, Akram
Domachevsky, Liran
Berger, Raanan
Leibowitz, Raya

April 2020

Lutetium-177-PSMA ([177Lu]-PSMA-617), a radiolabeled small molecule, binds with high affinity to pro...

Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.

Sartor, O
de Bono, J
Chi, KN
Fizazi, K
Herrmann, K
Rahbar, K
Tagawa, ST
Nordquist, LT
Vaishampayan, N
El-Haddad, G
Park, CH
Beer, TM
Armour, A
Pérez-Contreras, WJ
DeSilvio, M
Kpamegan, E
Gericke, G
Messmann, RA
Morris, MJ
Krause, BJ
VISION Investigators

June 2021

Background Metastatic castration-resistant prostate cancer remains fatal despite recent advances. Pr...

PSMA Theranostics: Current Status and Future Directions

Rahbar, Kambiz
Afshar Oromieh, Ali
Jadvar, Hossein
Ahmadzadehfar, Hojjat

January 2018

Prostate-specific membrane antigen (PSMA) is a promising target for imaging diagnostics and targeted...

Single-lesion Prostate-specific Membrane Antigen Protein Expression (PSMA) and Response to [177Lu]-PSMA-ligand Therapy in Patients with Castration-resistant Prostate Cancer

Judith Stangl-Kremser
Sazan Rasul
Jeffrey J. Tosoian
Simpa S. Salami
Alexander Zaslavsky
Aaron Udager
Peter Mazal
Renate Kain
Eva Comperat
Marcus Hacker
Alexander Haug
Markus Mitterhauser
Carmen Pozo-Salido
Christina Steinbach
Melanie R. Hassler
Gero Kramer
Shahrokh F. Shariat
Ganesh S. Palapattu

August 2021

Initial reports of a clinical response in patients treated with the radioligand [177Lu]-PSMA-617 for...

Real-world Outcomes and Predictive Biomarkers for 177Lutetium Prostate-specific Membrane Antigen Ligand Treatment in Metastatic Castration-resistant Prostate Cancer: A European Association of Urology Young Academic Urologists Prostate Cancer Working Group Multi-institutional Observational Study

Kafka, Mona
Horninger, Andreas
di Santo, Gianpaolo
Virgolini, Irene
Neuwirt, Hannes
Unterrainer, Lena M
Kunte, Sophie C
Deiss, Emil
Paffenholz, Pia
Heidenreich, Axel
Rasul, Sazan
Einspieler, Holger
Shariat, Shahrokh F
Rajwa, Pawel
Dozauer, Robert
Tsaur, Igor
Medlock, Ellen
Rölz, Niklas
Rausch, Steffen
la Fougère, Christian
Trautwein, Nils
Roesch, Marie C
Merseburger, Axel S
Zattoni, Fabio
Sepulcri, Matteo
Ladurner, Michael
Bektic, Jasmin
Gandaglia, Giorgio
Horninger, Wolfgang
Heidegger, Isabel

January 2023

Background: The European Association of Urology guidelines include the lutetium-177 (177Lu) PSMA-617...

USE OF 177Lu-PSMA FOR RADIONUCLIDE THERAPY IN PATIENTS WITH CASTRATE-RESISTANT PROSTATE CANCER

A. A. Medvedeva
V. I. Chernov
E. A. Usynin
R. V. Zelchan
O. D. Bragina
N. A. Lushnikova

June 2021

Purpose of the study: to present current data regarding challenges in treatment of castration-resist...

Near Complete Response to 177Lu-PSMA-DKFZ-617 Therapy in a Patient with Metastatic Castration Resistant Prostate Cancer

Madhav Prasad Yadav (4852228)
Sanjana Ballal (4852222)
Chandrasekhar Bal (4852225)

February 2018

Prostate specific membrane antigen, a type II transmembrane protein is an excellent target for th...

Preliminary experience with dosimetry, response and patient reported outcome after Lu-177-PSMA-617 therapy for metastatic castration-resistant prostate cancer

Fendler, Wolfgang P.
Reinhardt, Svenja
Ilhan, Harun
Delker, Andreas
Böning, Guido
Gildehaus, Franz J.
Stief, Christian
Bartenstein, Peter
Gratzke, Christian
Lehner, Sebastian
Rominger, Axel

January 2017

Prostate cancer can be targeted by ligands to the prostate-specific membrane antigen (PSMA). We aime...

Targeted Therapy for Metastatic Prostate Cancer with Radionuclides

Ahmadzadehfar, Hojjat

September 2016

Progression to androgen-independent status is the main cause of death in patients with metastatic pr...

177Lu-labeled PSMA targeting therapeutic with optimized linker for treatment of disseminated prostate cancer; evaluation of biodistribution and dosimetry

Abouzayed, Ayman
Seitova, Kamila
Lundmark, Fanny
Bodenko, Vitalina
Oroujeni, Maryam
Tolmachev, Vladimir
Rosenström, Ulrika
Orlova, Anna

January 2023

<bold>Introduction:</bold> Prostate specific membrane antigen (PSMA), highly expressed i...

Antibodies targeting Prostate-Specific Membrane Antigen positive prostate cancer: from diagnostic imaging to theranostics

Roumeguere T.
Aoun F.
Albisinni S.
Mjaess G.

January 2021

Purpose of review Targeting Prostate-Specific Membrane Antigen (PSMA) has paved the way for personal...

Projections for 90Y Radioimmunotherapy

In-j Lesion Detectability
Neeta P
Joseph A. O’donoghue
Michael J. Morris
Eze A. Wills
Lawrence H. Schwartz
Mithat Gonen
Howard I. Scher
Steven M. Larson
Chaitanya R. Divgi

December 2014

J591, a monoclonal antibody that targets the external domain of the prostate-specific membrane antig...

Phase II Study of Lutetium-177-Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer

Abstract

Extracted data

Phase II Study of Lutetium-177-Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer

Abstract

Extracted data

Related items

Related items